# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001193125-25-315918
Filing Date
2025-12-11
Accepted
2025-12-11 16:06:08
Documents
12
Period of Report
2025-12-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | evmn-20251211.htm iXBRL | 8-K | 52036
2 | EX-99.1 | evmn-ex99_1.htm | EX-99.1 | 199388
3 | GRAPHIC | img108483603_0.jpg | GRAPHIC | 645024
| Complete submission text file | 0001193125-25-315918.txt |  | 1266953

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | evmn-20251211.xsd | EX-101.SCH | 33245
14 | EXTRACTED XBRL INSTANCE DOCUMENT | evmn-20251211_htm.xml | XML | 4877

Mailing Address 1841 PAGE MILL RD PALO ALTO CA 94304
Business Address 1841 PAGE MILL RD PALO ALTO CA 94304 (650) 223-7745
Evommune, Inc. (Filer) CIK: 0002044725 (see all company filings)

EIN.: 850742575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42938 | Film No.: 251565026
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)